2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17±³À°ÀÏÀÚ : 2022-09-17
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
[¿Â/¿ÀÇÁ¶óÀÎ º´Çà] 2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ
´ã´çÀÚ : °°æ·¡
¿¬¶ôó : 02-3275-5335
À̸ÞÀÏ :
khfs3@khfs.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í ±³¼ö: 70,000¿øÀüÀÓÀÇ,Á¦¾à °ü·Ã Á¾»çÀÚ: 30,000¿ø Àü°øÀÇ, °£È£»ç, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ), ±ºÀÇ°ü: 10,000¿ø65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:00~09:15 Current status of heart transplantation in Korea with challenging case ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:15~09:35 2022 Update on heart transplant with case discussion Andreas Zuckermann(Medical University of Vienna, Austria)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:35~09:50 Antibody mediated rejection, what is new? ÃÖÈ¿ÀÎ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:50~10:05 Non-invasive monitoring of rejection after heart transplantation Josef Stehlik(University of Utah, USA)
Åä·Ð 09-17 ±×·£µåº¼·ë 10:05~10:30 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 09-17 ±×·£µåº¼·ë 10:30~11:00 Coffee Break ()
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:00~11:20 Prevalence and cumulative risk of familial idiopathic Ray Hershberger(The Ohio State University, USA)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:20~11:35 The state of precision cardiovascular medicine status in Korea ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:35~11:50 Genetic basis of myocardial recovery in dilated cardiomyopathy: Potential therapeutic implications Naveen Pereira(Mayo Clinic, USA)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:50~12:05 Contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of Hypertrophic Cardiomyopathy ÃÖÀÇ¿µ(¿¬¼¼ÀÇ´ë)
Åä·Ð 09-17 ±×·£µåº¼·ë 12:05~12:30 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
½Ä»ç 09-17 ±×·£µåº¼·ë 12:30~13:30 Lunch ()
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 13:30~13:45 Impella in advanced heart failure: Is revolutionized the field of mechanical circulatory support? Jun Nakata(Nippon Medical School Hospital, Japan)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 13:45~14:00 Overcome for donor shortage: How to improve donor heart utilization? ÇöÁØÈ£(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 14:00~14:15 Emergence of destination therapy in Japan Koichiro Kinugawa(University of Toyama, Japan)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 14:15~14:30 Heart transplantation in patients with mechanical circulatory support : What should be aware of? À̼ö¿ë(ºÎ»êÀÇ´ë)
Åä·Ð 09-17 ±×·£µåº¼·ë 14:30~15:00 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 09-17 ±×·£µåº¼·ë 15:00~15:20 Coffee Break ()
±âŸ 09-17 ±×·£µåº¼·ë 15:20~15:25 Keynote lecture (Session introduction): °³¿øÀÇÀÇ ÀÔÀå¿¡¼ ¹Ù¶óº» ½ÉºÎÀü Àü¹®ÀÇ ¿ªÇÒ ±èÇѼö(ºÐ´ç21¼¼±â³»°ú)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:25~15:40 Take 1. Heart failure diagnosis: Diagnosis of heart failure patient - Diagnostic work ( stage A to C) ȲÀÎâ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:40~15:55 Take 2. Chronic heart failure management: Medical treatment - How to implement guideline directed medical treatment ±èÇüÀ±(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:55~16:10 Take 3. Chronic heart failure management: Comorbidities - How to manage important comorbidities in heart failure ÀÌÁ¤Àº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 16:10~16:25 Take 4. Chronic heart failure Management: When to refer? ¼º¼®¿ì(Ãæ³²ÀÇ´ë)
Åä·Ð 09-17 ±×·£µåº¼·ë 16:25~16:50 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)